Rommelag Marks 50 Years of BFS Technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Rommelag Marks 50 Years of BFS Technology



Rommelag announced its 50th year of supplying blow-fill-seal machinery, with the brand name bottelpack. Rommelag is a member of the Hansen Group headed by CEO Bernd Hansen, with sales companies in Switzerland, Germany, the US, and China.

All bottelpack machines operate using the blow-fill-seal principle (BFS), a single automatic process in which containers are created from thermoplastic granules (blow), contents are inserted (fill) and closed (seal). BFS technology does not require the cleaning and sterilization processes that are used in other kinds of container production, according to Rommelag. Used for the aseptic packaging of sterile liquids, creams, ointments and vaccines, the machines are equipped with additional modules for QA and monitoring. Modules include aseptic systems for automatic cleaning and sterilization of lines that come into contact with products.

Rommelag reports that aseptic packaging by means of bottelpack BFS systems is gaining popularity and plastic materials offer advantages to manufacturers and users of infusion containers and ampoules. The packaging can be made very thin without risk of breaking, is easily collapsible, and is chemically inert.

Source: Rommelag

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here